循環器ジャーナル70巻1号

2022年01月発行

特集 心筋症診療のフロントライン—概念から最新の治療まで Ⅴ章　心肥大と出会ったら

—肥大を呈する二次性心筋症②—心アミロイドーシス

著者： 高潮征爾¹ 辻田賢一¹

所属機関： ¹熊本大学病院循環器内科

ページ範囲：P.137 - P.144

Point
・心アミロイドーシス診断のためには，まずはred flag所見を基に疑うことが重要である．
・M蛋白とピロリン酸シンチグラフィによる診断アルゴリズムを理解する．
・心アミロイドーシスは治療可能な疾患であり，早期診断が重要である．

参考文献

1）Izumiya Y, Takashio S, Oda S, et al : Recent advances in diagnosis and treatment of cardiac amyloidosis. J Cardiol 71 : 135-143, 2018

2）Kastritis E, Palladini G, Minnema MC, et al : Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 385 : 46-58, 2021

3）Maurer MS, Schwartz JH, Gundapaneni B, et al ; ATTR-ACT Study Investigators : Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018

4）日本循環器学会，日本アミロイドーシス学会，日本血液学会，他：2020年版　心アミロイドーシス診療ガイドライン．2020

5）Garcia-Pavia P, Rapezzi C, Adler Y, et al : Diagnosis and treatment of cardiac amyloidosis : a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42 : 1554-1568, 2021

6）Kittleson MM, Maurer MS, Ambardekar AV, et al ; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology : Cardiac Amyloidosis : Evolving Diagnosis and Management : A Scientific Statement From the American Heart Association. Circulation 142 : e7-e22, 2020

7）Yamada T, Takashio S, Arima Y, et al : Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail 7 : 2829-2837, 2020

8）Rapezzi C, Elliott P, Damy T, et al : Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy : Further analyses from ATTR-ACT. JACC Heart Fail 9 : 115-123, 2021

9）Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al : Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 : 2585-2594, 2015

10）Nitsche C, Scully PR, Patel KP, et al : Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol 77 : 128-139, 2021

11）Huntjens PR, Zhang KW, Soyama Y, et al : Prognostic Utility of Echocardiographic Atrial and Ventricular Strain Imaging in Patients With Cardiac Amyloidosis. JACC Cardiovasc Imaging 14 : 1508-1519, 2021

12）Takashio S, Yamamuro M, Izumiya Y, et al : Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail 5 : 27-35, 2018

13）Kumar S, Dispenzieri A, Lacy MQ, et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012

14）Grogan M, Scott CG, Kyle RA, et al : Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68 : 1014-1020, 2016

15）Gillmore JD, Damy T, Fontana M, et al : A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39 : 2799-2806, 2018

16）Martinez-Naharro A, Kotecha T, Norrington K, et al : Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging 12 : 810-819, 2019

17）Oda S, Kidoh M, Takashio S, et al : Identification of Wild-Type Transthyretin Cardiac Amyloidosis by Quantifying Myocardial Extracellular Volume Using Cardiac Computed Tomography in Atrial Arrhythmias. Circ Cardiovasc Imaging 13 : e010261, 2020

18）Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al : Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 38 : 1905-1908, 2017

19）Loungani RS, Rehorn MR, Geurink KR, et al : Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. Am Heart J 222 : 26-29, 2020

20）Donnellan E, Wazni O, Kanj M, et al : Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace 22 : 259-264, 2020

21）Damy T, Garcia-Pavia P, Hanna M, et al : Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial（ATTR-ACT）and long-term extension study. Eur J Heart Fail 23 : 277-285, 2021

22）Solomon SD, Adams D, Kristen A, et al : Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation 139 : 431-443, 2019

23）Fontana M, Martinez-Naharro A, Chacko L, et al : Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging 14 : 189-199, 2021